Studies have reported that the use of PI3K inhibitors can induce a decrease in c-Myc expression in pancreatic cancer cells (Sharma et al. 2015), while the use of c-Myc inhibitors can attenuate PI3K/AKT/mTOR-induced pancreatic cancer cell proliferation. Here, MYC is linked to pancreatic neoplasm.